Trial · NCT03123783
Adverse event totals21
The totals the trial posted for each group.
1 to 20 of 21
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation) | 1 | 3 |
| Total, all-cause mortality | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation) | 1 | 3 |
| Total, all-cause mortality | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation) | 0 | 3 |
| Total, all-cause mortality | Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3 | 18 | 53 |
| Total, all-cause mortality | Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3 | 4 | 38 |
| Total, all-cause mortality | Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | 4 | 14 |
| Total, all-cause mortality | Cohort 3B(Arm)/ PD1-NSCLC (Phase 2) | 9 | 28 |
| Total, other adverse events | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation) | 3 | 3 |
| Total, other adverse events | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation) | 3 | 3 |
| Total, other adverse events | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation) | 3 | 3 |
| Total, other adverse events | Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3 | 52 | 53 |
| Total, other adverse events | Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3 | 36 | 38 |
| Total, other adverse events | Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | 14 | 14 |
| Total, other adverse events | Cohort 3B(Arm)/ PD1-NSCLC (Phase 2) | 28 | 28 |
| Total, serious adverse events | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation) | 1 | 3 |
| Total, serious adverse events | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation) | 1 | 3 |
| Total, serious adverse events | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation) | 0 | 3 |
| Total, serious adverse events | Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3 | 25 | 53 |
| Total, serious adverse events | Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3 | 6 | 38 |
| Total, serious adverse events | Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | 6 | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03123783/event-totals